Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Migraine Headache
NCT04218539Phase 1Completed
- Sponsor
- Yale University
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in migraine (4 arms), sponsored by Yale University. Primary endpoints: Change in migraine attack frequency at 2 months, Change in pain intensity of migraine attacks at 2 months and 5 more. Started Aug 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04218539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218539.